Internet Delivered ERITA for Nonsuicidal Self-Injury (ERITA)

April 29, 2022 updated by: Clara Hellner Gumpert, Karolinska Institutet

Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study

To evaluate if Internet delivered emotion regulation individual therapy for adolescents is an efficacious treatment when delivered as adjunctive to treatment as usual compared to a control group consisting of treatment as usual.

Study Overview

Detailed Description

Statistical Analyses

Treatment effects will be evaluated according to the intention-to-treat principle. Primary end-point for all outcomes is post-treatment. Secondary end-point include a controlled 3 month follow-up.

Primary Analysis

The primary outcome analysis will include treatment group (ERITA , TAU) and weekly reports of NSSI frequency measured once every week 4 weeks prior to treatment start, once every week during treatment, and once every week four weeks after treatment termination. Regression analysis modelled for count data will be used to estimate trend over time. Four weeks after treatment termination will be considered primary endpoint. Pairwise contrasts (group x time interaction) from the regression model will be used to evaluate between-group differences at primary endpoint (4 weeks after treatment termination).

Secondary Analyses

Secondary outcomes measured once before, during, and after treatment will be analyzed in a similar fashion as for the primary outcome, modelled after data's distribution (count or continuous). Measures collected only once at baseline and post-treatment will be analyzed with regression analyses including treatment group (online ERITA , TAU) as the between-subjects factor, time (baseline to post) as the within-subjects factor, and group × time interactions, modelled after data's distribution (count or continuous).

Parallel process latent growth curve modeling will be used to determine whether change in week-to-week emotion dysregulation (DERS-16) during treatment mediate the overall effect of ERITA+ETAU on week-to-week change in the primary outcome self-rated NSSI frequency (DSHI-Y).

3 Month Follow-Up

Data collected at 3-month follow-up will be used to determine the extent to which potential treatment gains were maintained both within and between treatment conditions

Update 28 April 2022: As a secondary analyses, we also aim to investigate the effect of treatment moderators (primary aim) and predictors (secondary aim) on NSSI frequency one month after treatment termination. This update was submitted prior to conducting the analyses.

The selection of potential moderators was theoretically and empirically motivated. We will investigate the following variables (measured at baseline):

Age Difficulties in emotion regulation As measured with the Difficulties in Emotion Regulation Scale - 36 item version (DERS) Past month NSSI frequency As measured with the Deliberate Self-Harm Inventory Youth version (DSHI-Y) Global functioning As measured with the Childrens Global Assessment Scale Depressive symptoms As measured with the 21-item Depression Anxiety Stress Scales (DASS-21) Sleep difficulties As measured with the Insomnia Severity Index (ISI) Parental Minimization - discounting or devaluing the child's negative emotions/problems As measured with The Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A), subscale minimazation Level of suicidality As measured with the MINI-KID International Neuropsychiatric Interview, version 6

Study Type

Interventional

Enrollment (Actual)

166

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden, 113 64
        • Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council
      • Stockholm, Sweden, 113 64
        • Karolinska Institutet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 17 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ≥ 5 nonsuicidal self-injury episodes past year
  • ≥ 1 nonsuicidal self-injury episodes past month
  • having at least one parent who committed to participate in the parent program

Exclusion Criteria:

  • Severe suicidal ideation
  • a diagnosis of psychotic or bipolar I disorder or ongoing (past month) substance dependence
  • the presence of co-occurring psychological disorders that required immediate treatment (i.e., severe anorexia nervosa)
  • insufficient understanding of the Swedish language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Adjunctive Internet-delivered ERITA
Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
Active Comparator: Treatment as usual
Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
Treatment as usual as provided in the community.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Deliberate Self-Harm Inventory Youth version (DSHI-Y)
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Frequency of nonsuicidal self-injury
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Difficulties in emotion regulation as primary potential mechanism of change. Ranges from 16-80, with higher scores indicating more difficulties.
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Difficulties in Emotion Regulation Scale - 36 item version (DERS)
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Difficulties in emotion regulation. Ranges from 36-180, with higher scores indicating more difficulties.
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
the 21-item Depression Anxiety Stress Scales (DASS-21)
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Symptoms of depression, anxiety and stress. Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating more symptoms.
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Borderline Symptom List Supplement
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Impulsive self-destructive behaviors
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
Acceptance and Action Questionnaire
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Acceptance and valued actions. Ranges from 7-49, with higher scores indicating less acceptance and valued actions.
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Childrens Global Assessment Scale
Time Frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
Global functioning. Ranges from 1-100, with higher scores indicating better functioning.
Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
The Clinical Global Impressions -Severity and Improvement scales
Time Frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
Global symptom severity and improvement. Severity of illness scale ranges from 1-7, with higher scores indicating higher severity of illness. Global improvement scale ranges from 1-7 with lower scores indicating more improvement.
Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Short version of the Experiences in Close Relationships Scale - Revised Child version
Time Frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Experiences in close relationships. Ranges from 12-84, with higher scores indicating greater problems.
Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Generalised Anxiety Disorder 7-item scale
Time Frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Worry. Ranges 0-21, with higher scores indicating more worry.
Change from baseline, once every second week during treatment (0-12 weeks after baseline)
Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Costs associated with psychiatric illness
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Kidscreen-10
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Quality of life. Ranges 11-55, with higher scores indicating higher quality in life.
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Patient Internet-delivered cognitive behavioral Adherence Scale
Time Frame: 6 and 12 weeks after baseline
Patient adherence to treatment. Ranges from 0-20, with higher scores indicating higher adherence.
6 and 12 weeks after baseline
Working Alliance Inventory
Time Frame: 4 weeks after treatment starts
Working alliance with online therapist
4 weeks after treatment starts
The Coping with Children's Negative Emotions Scale Adolescent Version
Time Frame: Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended
Parents' perceived ability to cope with children's negative emotions. Three subscales will be used derived to reflect the specific types of coping response parents tend to use in these situations (punitive reactions, problem focused reactions, and minimization reactions). Each subscale ranges from 1-7.
Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended
The Client Satisfaction Questionnaire
Time Frame: 12 weeks after treatment starts
Client satisfaction with treatment. Ranges from 8-32 with higher scores indicating greater treatment satisfaction.
12 weeks after treatment starts
Adverse Events
Time Frame: 12 weeks after treatment starts
Self-rating scale that measures adverse events related to treatment
12 weeks after treatment starts
Credibility/Expectancy Questionnaire
Time Frame: 1 week after treatment starts
Treatment credibility and expectancy. Ranges from 0-50 with higher scores indicating greater credibility/expectancy.
1 week after treatment starts

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Clara Hellner, PhD, MD, Karolinska Institutet

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2017

Primary Completion (Actual)

January 7, 2021

Study Completion (Actual)

October 17, 2021

Study Registration Dates

First Submitted

November 2, 2017

First Submitted That Met QC Criteria

November 21, 2017

First Posted (Actual)

November 27, 2017

Study Record Updates

Last Update Posted (Actual)

May 5, 2022

Last Update Submitted That Met QC Criteria

April 29, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2017/10 BIP ERITA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nonsuicidal Self-injury

Clinical Trials on Emotion regulation individual therapy

Subscribe